Skip to main content
Log in

Practical Considerations and Guidelines for the Management of Community-Acquired Pneumonia

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Community-acquired pneumonia (CAP) is a common condition which has a significant mortality. The management of a patient with CAP is centred around assessment and correction of gas exchange and fluid balance together with administration of appropriate antibiotics. Up to 10 different pathogens regularly cause CAP, of which Streptococcus pneumoniae is the most important. These different pathogens cannot be distinguished by clinical features or simple laboratory tests. Microbiological tests are slow and insensitive, so empirical therapy is necessary, at least initially. Accurate assessment of illness severity is the most important factor determining initial management, since this assists the decision of whether to admit the patient to hospital in addition to guiding antibiotic choice and route of administration.

Two different approaches to severity assessment are outlined. Our antibiotic recommendation for empirical therapy for the patient managed at home and the previously fit patient admitted to hospital is amoxicillin. Amoxicillin/clavulanate plus a macrolide is our choice for the severely ill previously fit patient and a third-generation cephalosporin plus a macrolide is recommended for the severely ill patient with comorbidity. Alternative pathogens and specific treatment regimens are also described. There may be several causes of treatment failure, and in patients who fail to respond to therapy, it is essential to review all the initial clinical and laboratory information, which if necessary must be repeated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Melbye H, Berdal BP, Straume B, et al. Pneumonia — a clinical or radiographic diagnosis. Scand J Infect Dis 1992; 24: 647–55

    Article  PubMed  CAS  Google Scholar 

  2. Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987: I: 671–4

    Article  Google Scholar 

  3. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Finland. Am J Epidemiol 1993; 137: 977–88

    PubMed  CAS  Google Scholar 

  4. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96: 313–20

    Article  PubMed  CAS  Google Scholar 

  5. Macfarlane JT, Finch RG, Ward MJ, et al. Hospital study of adult community-acquired pneumonia. Lancet 1982; II: 255–8

    Article  Google Scholar 

  6. British Thoracic Society. Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors, and outcome. Q J Med 1987; 62: 195–220

    Google Scholar 

  7. Fang G-D, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69: 307–16

    Article  PubMed  CAS  Google Scholar 

  8. Mundy LM, Auwaerter PG, Oldach D, et al. Community— acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995; 152: 1309–15

    PubMed  CAS  Google Scholar 

  9. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalisation: 5 year prospective study. Rev Infect Dis 1989; 11: 586–99

    Article  PubMed  CAS  Google Scholar 

  10. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1996; 275: 134–41

    Article  PubMed  CAS  Google Scholar 

  11. Almirall J, Morato I, Riera F, et al. Incidence of community acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. Eur Respir J 1993; 6: 14–8

    PubMed  CAS  Google Scholar 

  12. Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508–15

    Article  PubMed  CAS  Google Scholar 

  13. Berntsson E, Lagergard T, Strannegard O, et al. Etiology of community-acquired pneumonia in outpatients. Eur J Clin Microbiol 1986; 5: 446–7

    Article  PubMed  CAS  Google Scholar 

  14. Ausina V, Coll P, Sambeat M, et al. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur J Clin Microbiol Infect Dis 1988;7: 343–7

    Article  Google Scholar 

  15. Berntsson E, Bomberg J, Lagergard T, et al. Etiology of community-acquired pneumonia in patients requiring hospitalisation. Eur J Clin Microbiol 1985; 4: 268–72

    Article  PubMed  CAS  Google Scholar 

  16. Bohte R, van Furth R, van den Broek P J. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50: 543–7

    Article  PubMed  CAS  Google Scholar 

  17. Holmberg H. Aetiology of community-acquired pneumonia in hospital-treated patients. Scand J Infect Dis 1987; 19: 491–501

    Article  PubMed  CAS  Google Scholar 

  18. Levy M, Dromer F, Brion N, et al. Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988; 92: 43–8

    Article  Google Scholar 

  19. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179–84

    Article  PubMed  CAS  Google Scholar 

  20. Ortqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalisation. Eur Respir J 1990; 3: 1105–13

    PubMed  CAS  Google Scholar 

  21. Steinhoff D, Lode H, Ruckdeschel G, et al. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis 1996; 22: 958–64

    Article  PubMed  CAS  Google Scholar 

  22. British Thoracic Society Research Committee and the Puic Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia in the intensive care unit. Respir Med 1992; 86: 7–13

    Article  Google Scholar 

  23. Moine P, Vercken J-B, Chevret S, et al. Severe community-acquired pneumonia: etiology, epidemiology and prognosis factors. Chest 1994; 105: 1487–95

    Article  PubMed  CAS  Google Scholar 

  24. Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis 1985; 17: 377–86

    PubMed  CAS  Google Scholar 

  25. Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312–8

    Article  PubMed  CAS  Google Scholar 

  26. Woodhead MA, Macfarlane JT, Rodgers FG, et al. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985; 10: 204–10

    Article  PubMed  CAS  Google Scholar 

  27. Sobradillo V, Ansola P, Baranda F, et al. Q fever pneumonia: a review of 164 community-acquired cases in the Basque country. Eur Respir J 1989; 2: 263–6

    PubMed  CAS  Google Scholar 

  28. Marrie TJ, Haldane EV, Faulkner RS, et al. The importance of Coxiella burnetii as a cause of pneumonia in Nova Scotia. Can J Pu Health 1985; 76: 233–6

    CAS  Google Scholar 

  29. Feldman C, Kallenbach JM, Levy H, et al. Community-acquired pneumonia of diverse aetiology: prognostic features in patients admitted to an intensive care unit and a ‘severity of illness’ score. Intensive Care Med 1989; 15: 302–7

    Article  PubMed  CAS  Google Scholar 

  30. Chan CHS, Cohen M, Pang J. A prospective study of community-acquired pneumonia in Hong Kong. Chest 1992; 101: 442–6

    Article  PubMed  CAS  Google Scholar 

  31. Alkhaeyer M, Jenkins PF, Harrison BDW. The outcome of community-acquired pneumonia treated on the intensive care unit. Respir Med 1990; 84: 13–6

    Article  Google Scholar 

  32. Hirani N, Macfarlane JT. Impact of management guidelines on the outcome of severe community-acquired pneumonia. Thorax 1997; 52: 17–21

    Article  PubMed  CAS  Google Scholar 

  33. Sorensen J, Cederholm I, Carlsson C. Pneumonia: a deadly disease despite intensive care treatment. Scand J Infect Dis 1986; 18: 329–35

    Article  PubMed  CAS  Google Scholar 

  34. Pachon J, Prados MD, Capote F, et al. Severe community-acquired pneumonia: etiology, prognosis and treatment. Am Rev Respir Dis 1990; 142: 369–73

    PubMed  CAS  Google Scholar 

  35. Leroy O, Santre C, Beuscart C, et al. A five year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21: 24–31

    Article  PubMed  CAS  Google Scholar 

  36. Torres A, Dorca J, Zalacain R, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicentre study. Am J Respir Crit Care Med 1996; 154: 1456–61

    PubMed  CAS  Google Scholar 

  37. Venkatesan P, Gladman J, Macfarlane JT, et al. A hospital study of community-acquired pneumonia in the elderly. Thorax 1990; 45: 254–8

    Article  PubMed  CAS  Google Scholar 

  38. Bourke SJ, Lightfoot NF. Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis. Thorax 1995; 50 Suppl. 1: S43–8

    Article  PubMed  Google Scholar 

  39. Levy H. Hantavirus infection. Curr Opin Infect Dis 1997; 10: 103–8

    Article  Google Scholar 

  40. Woodhead MA. Atypical pneumonia. Curr Opin Infect Dis 1997; 10: 101–2

    Article  Google Scholar 

  41. Woodhead MA, Arrowsmith J, Chamberlain-Webber R, et al. The value of routine microbial investigation in community-acquired pneumonia. Respir Med 1991; 85: 313–7

    Article  PubMed  CAS  Google Scholar 

  42. Manresa F, Dorca J. Needle aspiration techniques in the diagnosis of pneumonia. Thorax 1991; 46: 601–3

    Article  PubMed  CAS  Google Scholar 

  43. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalised for community-acquired pneumonia. Ann Intern Med 1991; 115: 428–36

    PubMed  CAS  Google Scholar 

  44. Karalus NC, Cursons RC, Leng RA, et al. Community-acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991; 46: 413–8

    Article  PubMed  CAS  Google Scholar 

  45. Neill AM, Martin IR, Weir R, et al. Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010–6

    Article  PubMed  CAS  Google Scholar 

  46. Fine MJ, Aue TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50

    Article  PubMed  CAS  Google Scholar 

  47. Mandell LA, Niederman M, The Canadian community-acquired pneumonia consensus conference group. Can J Infect Dis 1993; 4: 25–8

    PubMed  CAS  Google Scholar 

  48. Niederman MD, Low BJ, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26

    PubMed  CAS  Google Scholar 

  49. Société de Pathologie Infectieuse de Langue Française. Infections des voies respiratoires: conférence de concensus en thérapeutique anti-infectieuse. Rev Med Infect 1991; 21: 1s–8s

    Google Scholar 

  50. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 349–50

    Google Scholar 

  51. SEPAR (Spanish Thoracic Society). National recommendations for diagnosis and treatment of community acquired pneumonia. Barcelona: Ediciones Doyma SA, 1992

    Google Scholar 

  52. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474–80

    Article  PubMed  CAS  Google Scholar 

  53. Drusano G. Pharmacology of anti-infective agents. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Chap 14. New York: Churchill Livingstone, 1995: 225–33

    Google Scholar 

  54. Johnson AP, Speller DCE, George RC, et al. Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995. BMJ 1996; 312: 1454–6

    Article  PubMed  CAS  Google Scholar 

  55. Committee on Safety of Medicines. Current Proems. Curr Pro Pharmacovig 1996; 21: 6

    Google Scholar 

  56. Woodhead MA, Radvan J, Macfarlane JT. Adult community-acquired staphylococcal pneumonia in the antibiotic era: a review of 61 cases. Q J Med 1987; 64: 783–90

    PubMed  CAS  Google Scholar 

  57. Gialdroni Grassi G, Brumpt I. Sparfloxacin empirical therapy in community-acquired pneumonia: results of a meta-analysis of 2 comparative studies. Drugs 1995; 49 Suppl. 2: 406–8

    Article  Google Scholar 

  58. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618–24

    Article  PubMed  CAS  Google Scholar 

  59. Weingarten SR, Riedinger MS, Varis G, et al. Identification of low-risk hospitalised patients with pneumonia: implications for early conversion to oral antimicrobial therapy. Chest 1994; 105: 1109–15

    Article  PubMed  CAS  Google Scholar 

  60. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalised patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273–6

    Article  PubMed  CAS  Google Scholar 

  61. Macfarlane JT, Miller AC, Smith WHR, et al. Comparative radiographic features of community-acquired legionnaires’ disease, pneumococcal pneumonia, mycoplasma pneumonia and psittacosis. Thorax 1984; 39: 28–33

    Article  PubMed  CAS  Google Scholar 

  62. Holmberg H, Kragsbjerg P. Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow up. Scand J Infect Dis 1993; 25: 93–100

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Roger G. Finch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finch, R.G., Woodhead, M.A. Practical Considerations and Guidelines for the Management of Community-Acquired Pneumonia. Drugs 55, 31–45 (1998). https://doi.org/10.2165/00003495-199855010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199855010-00003

Keywords

Navigation